Trial Profile
Xarelto (Rivaroxaban) Risk Minimisation Plan Evaluation: Patient and Physician Knowledge of Key Safety Messages
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke
- Focus Adverse reactions
- 21 May 2015 Status changed from recruiting to active, no longer recruiting as reported by UK Clinical Trials Register.
- 22 Apr 2015 New trial record